Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy

Journal of Virology

Volumn 74, Issue 15, 2000, Pages 6821-6831

  Durbin, Anna P ^a,c   Skiadopoulos, Mario H ^a   McAuliffe, Josephine M ^a   Riggs, Jeffrey M ^a   Surman, Sonja R ^a   Collins, Peter L ^a   Murphy, Brian R ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MSC 0720 ^*  (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS HEMAGGLUTININ; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; IMMUNIZATION; MEASLES; MEASLES VIRUS; NONHUMAN; OPEN READING FRAME; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; SYRIAN HAMSTER; VIRUS ATTENUATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; CELLS, CULTURED; CRICETINAE; HEMAGGLUTININS, VIRAL; HUMANS; INFANT; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MESOCRICETUS; MOLECULAR SEQUENCE DATA; PARAINFLUENZA VIRUS 3, HUMAN; TEMPERATURE; VACCINATION; VACCINES, SYNTHETIC; VIRUS REPLICATION;

EID: 0033940077     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.15.6821-6831.2000     Document Type: Article

References (68)

1. Albrecht, P., F. A. Ennis, E. J. Saltzman, and S. Krugman. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715-718.
2. Black, F. L., and S. R. Sheridan. 1960. Studies on an attenuated measles-virus vaccine. IV. Administration of vaccine by several routes. N. Engl. J. Med. 263:165-169.
3. Blanchard, T. J., A. Alcami, P. Andrea, and G. L. Smith. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79:1159-1167.
4. Carroll, M. W., and B. Moss. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
5. Centers for Disease Control and Prevention. 1997. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. Morbid. Mortal. Weekly Rep. 46:1-21.
6. Chen, R. T., L. E. Markowitz, P. Albrecht, J. A. Stewart, L. M. Mofenson, S. R. Preblud, and W. A. Orenstein. 1990. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162:1036-1042.
7. Coates, H. V., D. W. Alling, and R. M. Chanock. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:299-313.
8. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1352. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
9. Crowe, J. E., Jr., P. T. Bui, G. R. Siber, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1995. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13:847-855.
10. Cutts, F. T., C. J. Clements, and J. V. Bennett. 1997. Alternative routes of measles immunization: a review. Biologicals 25:323-338.
11. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
12. Drillien, R., D. Spehner, A. Kirn, P. Giraudon, R. Buckland, F. Wild, and J. P. Lecocq. 1988. Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglulinin or the fusion protein. Proc. Natl. Acad. Sci. USA 85:1252-1256.
13. Durbin, A. P., C. J. Cho, W. R. Elkins, L. S. Wyatt, B. Moss, and B. R. Murphy. 1999. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J. Infect. Dis. 179:1345-1351.
14. Durbin, A. P., S. L. Hall, J. W. Siew, S. S. Whitehead, P. L. Collins, and B. R. Murphy. 1997. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 235:323-332.
15. Durbin, A. P., J. M. McAuliffe, P. L. Collins, and B. R. Murphy. 1999. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 261:319-330.
16. Durbin, A. P., J. W. Siew, B. R. Murphy, and P. L. Collins. 1997. Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology 234:74-83.
17. Durbin, A. P., L. S. Wyatt, J. Siew, B. Moss, and B. R. Murphy. 1998. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 16:1324-1330.
18. Fenner, F., D. A. Henderson, I. Arita, Z. Kezek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
19. Fooks, A. R., E. Schadeck, U. G. Liebert, A. B. Dowsett, B. K. Rima, M. Steward, J. R. Stephenson, and G. W. Wilkinson. 1995. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210:456-465.
20. Fulginiti, V. A., J. J. Eller, A. W. Downie, and C. H. Kempe. 1967. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202:1075-1080.
21. Galletti, R., P. Beauverger, and T. F. Wild. 1995. Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses. Vaccine 13:197-201.
22. Gellin, B. G., and S. L. Katz. 1994. Measles: state of the art and future directions. J. Infect. Dis. 170:3-14.
23. Griffin, D. E., and W. J. Bellini. 1996. Measles virus, p. 1267-1312. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, vol. 1. Lippincott-Raven Publishers, Philadelphia, Pa.
24. Hall, S. L., C. M. Sarris, E. L. Tierney, W. T. London, and B. R. Murphy. 1993. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees. J. Infect. Dis. 167:958-962.
25. Hall, S. L., A. Stokes, E. L. Tierney, W. T. London, R. B. Belshe, F. C. Newman, and B. R. Murphy. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:173-184.
26. Halsey, N. A., R. Boulos, F. Mode, J. Andre, L. Bowman, R. G. Yaeger, S. Toureau, J. Rohde, and C. Boulos. 1985. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N. Engl. J. Med. 313:544-549.
27. Hoffman, M. A., and A. K. Banerjee. 1997. An infectious clone of human parainfluenza virus type 3. J. Virol. 71:4272-4277.
28. Holt, E. A., L. H. Moulton, G. K. Siberry, and N. A. Halsey. 1993. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168:1087-1096.
29. Hummel, K. B., and W. J. Bellini. 1995. Localization of monoclonal antibody epitopes and functional domains in the hemagglutinin protein of measles virus. J. Virol. 69:1913-1916.
30. Janeway, C. A. 1945. Use of concentrated human serum gamma-globulin in the prevention and attenuation of measles. Bull. N. Y. Acad. Med. 21:202-212.
31. Karron, R. A., M. Makhene, K. Gay, M. H. Wilson, M. L. Clements, and B. R. Murphy. 1996. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr. Infect. Dis. J. 15: 650-654.
32. Karren, R. A., P. F. Wright, S. L. Hall, M. Makhene, J. Thompson, B. A. Burns, S. Tollefson, M. C. Steinhoff, M. H. Wilson, D. O. Harris, M. L. Clements, and B. R. Murphy. 1995. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J. Infect. Dis. 171:1107-1114.
33. Karron, R. A., P. F. Wright, F. K. Newman, M. Makhene, J. Thompson, R. Samorodin, M. H. Wilson, E. L. Anderson, M. L. Clements, B. R. Murphy, and R. B. Belshe. 1995. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 172:1445-1450.
34. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
35. Kok, P. W., P. R. Kenya, and H. Ensering. 1983. Measles immunization with further attenuated heat-stable measles vaccine using five different methods of administration. Trans. R. Soc. Trop. Med. Hyg. 77:171-176.
36. Krugman, S. 1963. The clinical use of gamma globulin. N. Engl. J. Med. 269:195-201.
37. Kunkel, T. A., J. D. Roberts, and R. A. Zakour. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154:367-382.
38. Markowitz, L. E., J. Sepulveda, J. L. Diaz-Ortega, J. L. Valdespino, P. Albrecht, E. R. Zell, J. Stewart, M. L. Zarate, and R. H. Bernier. 1990. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N. Engl. J. Med. 322:580-587. (Erratum, 332:863.)
39. Marx, A.. T. J. Torok, R. C. Holman, M. J. Clarke, and L. J. Anderson. 1997. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J. Infect. Dis. 176:1423-1427.
40. Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the patenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentbl. Bakteriol. 167:375-390. (In German.)
41. Murphy, B. R., R. A. Olmsted, P. L. Collins, R. M. Chanock, and G. A. Prince. 1988. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J. Virol. 62:3907-3910.
42. Nader, P., M. Horwitz, and J. Rousseau. 1968. Atypical exanthem following exposure to natural measles. Eleven cases in children previously inoculated with killed vaccine. J. Pediatr. 72:22-28.
43. Osterhaus, A., G. van Amerongen, and R. van Binnendijk. 1998. Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine. Vaccine 16:1479-1481.
44. Polack, F. P., P. G. Auwaerter, S. H. Lee, H. C. Nousari, A. Valsamakis, K. M. Leiferman, A. Diwan, R. J. Adams, and D. E. Griffin. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:629-634.
45. Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
46. Sabin, A. B., P. Albrecht, A. K. Takeda, E. M. Ribeiro, and R. Veronesi. 1985. High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J. Infect. Dis. 152:1231-1237.
47. Schnell, M. J., L. Buonocore, E. Kretzschmar, E. Johnson, and J. K. Rose. 1996. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. USA 93:11359-11365.
48. Sheshberadaran, H., E. Norrby, and K. W. Rammohan. 1985. Monoclonal antibodies against five structural components of measles virus. II. Characterization of five cell lines persistently infected with measles virus. Arch. Virol. 83:251-268.
49. Siegrist, C. A., M. Cordova, C. Brandt, C. Barrios, M. Berney, C. Teugne, J. Kovarik, and P. H. Lambert. 1998. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine 16:1409-1414.
50. Siegrist, C. A., and P. H. Lambert 1998. Maternal immunity and infant responses to immunization: factors influencing infant responses. Dev. Biol. Stand. 95:133-139.
51. Simasathien, S., S. Migasenu, W. Bellini, R. Samakoses, P. Pitisuttitham, W. Bupodom, J. Heath, L. Andersen, and J. Bennett. 1997. Measles vaccination of Thai infants by intranasal and subcutaneous routes: possible interference from respiratory infections. Vaccine 15:329-334.
52. Skiadopoulos, M. H., A. P. Durbin, J. M. Tatem, S. L. Wu, M. Paschalis, T. Tao, P. L. Collins, and B. R. Murphy. 1998. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J. Virol. 72:1762-1768.
53. Skiadopoulos, M. H., S. Surman, J. M. Tatem, M. Paschalis, S. L. Wu, S. A. Udem, A. P. Durbin, P. L. Collins, and B. R. Murphy. 1999. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J. Virol. 73:1374-1381.
54. Skiadopoulos, M. H., T. Tao, S. R. Surman, P. L. Collins, and B. R. Murphy. 1999. Generation of a parainfluenza virus type I vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18:503-510.
55. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schafer, and A. Holzner. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 99: 2386-2392. (In German.)
56. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
57. Tao, T., M. H. Skiadopoulos, A. P. Durbin, F. Davoodi, P. L. Collins, and B. R. Murphy. 1999. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine 17:1100-1108.
58. Taylor, J., R. Weinberg, J. Tartaglia, C. Richardson, G. Alkhatib, D. Briedis, M. Appel, E. Norton, and E. Paoletti. 1992. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187:321-328.
59. Taylor, W. R., R. K. Mambu, M. ma-Disu, and J. M. Weinman. 1988. Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life. Am. J. Epidemiol. 127:788-794.
60. van Binnendijk, R. S., M. C. Poelen, G. van Amerongen, P. de Vries, and A. D. Osterhaus. 1997. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:524-532.
61. van Wyke Coelingh, K. L., B. R. Murphy, P. L. Collins, A. M. Lebacq-Verheyden, and J. F. Battey. 1987. Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus. Virology 160:465-472.
62. van Wyke Coelingh, K. L., C. Winter, and B. R. Murphy. 1985. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology 143:569-582.
63. Werner, G. T., U. Jentzsch, E. Metzger, and J. Simon. 1980. Studies on poxvirus infections in irradiated animals. Arch. Virol. 64:247-256.
64. Wild, F., P. Giraudon, D. Spehner, R. Drillien, and J. P. Lecocq. 1990. Fowlpox virus recombinant encoding the measles virus fusion protein: protection of mice against fatal measles encephalitis. Vaccine 8:441-442.
65. Wild, T. F., A. Bernard, D. Spehner, and R. Drillien. 1992. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. J. Gen. Virol. 73:359-367.
66. Wild, T. F., E. Malvoisin, and R. Buckland. 1991. Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion. J. Gen. Virol. 72:439-442.
67. World Health Organization. 1994. Expanded programme on immunization-accelerated measles strategies. Weekly Epidemiol. Rec. 69:229-234.
68. Wyatt, L. S., B. Moss, and S. Rozenblalt. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205.